In this free webinar, understand the role of compendia as a bridge between FDA approvals and payer coverage, especially in cases of off-label use, and clarify common misconceptions around off-label ...

In accordance with federal law, the Centers for Medicare and Medicaid Services (CMS) must reimburse cancer drugs used off-label if one of five authorized drug compendia consider such treatment ...

Compendia Bioscience has announced a strategic collaboration with MDS Pharma Services to deliver OncoPredictor, a novel solution for improved cancer drug development. OncoPredictor combines MDS Pharma ...

The compendia used to make coverage determinations for Medicare Part D are inadequate for many dermatologic diseases, a recent investigation has found. Out of more than 200 evidence-based treatments ...

is exploring how to leverage the value of its extensive data to secure new revenue.The Ann Arbor-based health care IT and consulting services firm is also looking to add five employees for a total of ...

Beyond Jeopardy!: Harnessing IBM's Watson to improve oncology decision making. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include a full text ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...